Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions:   Bladder Urothelial Carcinoma;   Distal Urethral Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma;   Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter;   Proximal Urethral Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Urethra Carcinoma;   Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter;   Regional Urothelial Carcinoma of the Renal Pelvis and Ureter;   Stage IV Bladder Cancer;   Stage IV Prostate Cancer;   Stage IV Urethral Cancer;   Ureter CarcinomaInterventions:   Drug: Gemcitabine Hydrochloride;   Drug: Cisplatin;   Other: Placebo;   Biological: Bevacizumab;   Other: Laboratory Biomarker AnalysisSponsor:   National Cancer Institute (NCI)Active, not recruiting - verified November 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials